Martoma To Stand Trial In November

Jun 6 2013 | 11:29am ET

Mathew Martoma, the former SAC Capital Advisors portfolio manager whose alleged insider-trading has brought that firm to its knees, will face trial later this year on fraud charges.

U.S. District Judge Paul Gardephe said yesterday that Martoma's trial will begin on Nov. 4. He is accused of earning SAC about $276 million in illicit profits trading on tips about Alzheimer's disease drug trials.

Martoma's lawyer, Richard Strassberg, told Gardephe he might need more time, citing both the prosecution's apparent plan to file a superseding indictment and another trial that he is working on.

Strassberg asked Gardephe to set a February trial date. The judge said he was reluctant to do so, but told Strassberg he would postpone the trial if necessary.

"I'm not closing the door to a later trial date, but if you feel, as you get close to your trial date before Judge Rakoff, that you're facing insurmountable difficulties or that you'll still be on trial before Judge Rakoff, you'll alert me to that and I'll make an appropriate adjournment."

Martoma is accused of illegally trading shares of Elan Corp. and Wyeth, based on tips received from a doctor overseeing the drug trials. The doctor, Sidney Gilman, is a former professor at the University of Michigan and is cooperating with the probe.

Strassberg told Gardephe that he might seek to have the charges related to Elan, which is based in Dublin and trades abroad, dismissed, citing a 2010 U.S. Supreme Court ruling that U.S. securities laws do not protect foreign investors who trade overseas.

In addition, Gardephe set a June 18 conference to discuss Michigan's reluctance to give lawyers from both sides access to Gilman's computer at the university, which says it is wary of producing confidential information about drug trials and patients.

"If the university's position is that they want to quash a subpoena, I want a filing from them," Gardephe said.

The case against Martoma is the only one of the nine brought so far against SAC employees that is directly tied to firm founder Steven Cohen. Prosecutors do not, however, allege that Cohen knew the information he got from Martoma was non-public.


In Depth

Q&A: Brevan Howard’s Charlotte Valeur Talks Strategy

Sep 18 2014 | 11:18am ET

Charlotte Valeur chairs the board of Brevan Howard Credit Catalysts, an LSE listed...

Lifestyle

Hedgies Rock Out For Children's Charity

Sep 15 2014 | 8:40am ET

It's that time of year again—when hedgies trade in their spreadsheets for guitars...

Guest Contributor

Volkered: How Financial Sector Reforms are Creating Opportunities for Hedge Funds

Sep 16 2014 | 11:28am ET

New regulations have dramatically curtailed proprietary trading activity in investment...

 

Hard Assets Trending

Futures Trending

Editor's Note

    Get A Sneak Peak Of The Alpha Pages

    Aug 25 2014 | 11:21am ET

    As many of you know, FINalternatives was recently acquired by the owners of Futures magazine, a firm called The Alpha Pages LLC. Today marks the soft-launch of a new sister site for both publications. As its name suggests, The Alpha Pages will cover all types of alternative investments, going far beyond the more well-known ones such as hedge funds and private equity. Read more…

 

Futures Magazine

September 2014 Cover

The London Whale: Rogue risk management

Credit default swaps brought down the London Whale and cost JPMorgan $6.2 billion. Here is how it happened.

The Alpha Pages

TAP July/August 2014 Cover

The Alpha Pages Interview: Senator Rand Paul

Senator Paul sat down in the debut series of the Alpha Pages Interview to discuss the broken tax code, regulation surrounding Bitcoin, and his plans for the 2016 Presidential election.